Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tobramycin/dexamethasone - Eyevance Pharmaceuticals

Next Previous
Drug Profile

Tobramycin/dexamethasone - Eyevance Pharmaceuticals

Alternative Names: Dexamethasone/tobramycin - Alcon; TobraDex; Tobradex AF; TobraDex ST

Latest Information Update: 27 Mar 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alcon
  • Class Aminoglycosides; Anti-inflammatories; Antibacterials; Corticosteroids; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Pregnadienetriols; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Immunosuppressants; Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Ocular inflammation

Most Recent Events

  • 02 Mar 2020 Eyevance Pharmaceuticals launched tobramycin/dexamethasone for Ocular inflammation in USA (Ophthalmic)
  • 24 Feb 2020 Eyevance Pharmaceuticals announces intention launch tobramycin/dexamethasone on March 2, 2020
  • 16 Oct 2019 Eyevance Pharmaceuticals acquires Tobramycin/dexamethasone from Novartis

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top